SCHEMBL12848962

SCHEMBL12848962

O=C(Nc1c(F)cccc1Cl)c1cc2c(s1)-c1cc(-c3cccnc3)ccc1CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
ABCB1 P08183 4/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LCK P06239 1/20 0.37
CNR1 P21554 1/20 0.37
KDR P35968 1/20 0.37
DHODH Q02127 1/20 0.37
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
KDM4E B2RXH2 1/20 0.35
P2RX7 Q99572 1/20 0.35
ABL1 P00519 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12848727 0.94 MEN1 (0.42) MEN1KMT2ATDP1CYP11B1CYP11B2
SCHEMBL12848481 0.94 MEN1 (0.42) MEN1KMT2ATDP1ABCB1CYP11B1
SCHEMBL12848433 0.89 MEN1 (0.42) MEN1KMT2ATDP1ABCB1CYP11B1
SCHEMBL12848728 0.86 KDM4E (0.50) MEN1KMT2ATDP1ABCB1CYP11B1
SCHEMBL12848881 0.84 ABCB1 (0.48) MEN1KMT2ATDP1ABCB1CYP11B1
SCHEMBL12848954 0.84 NOTUM (0.40) MEN1KMT2ATDP1NPC1RAB9A
SCHEMBL12848957 0.83 ABCB1 (0.51) MEN1KMT2ATDP1ABCB1CYP11B2
SCHEMBL12848961 0.82 ABCB1 (0.41) ABCB1CYP11B1CYP11B2NPC1RAB9A
SCHEMBL12848824 0.82 MEN1 (0.48) MEN1KMT2ATDP1CYP11B1CYP11B2
SCHEMBL12848956 0.81 NOTUM (0.40) MEN1KMT2ATDP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES TSLP, NFATC1, IL5 MEN1 4414/4885KMT2A 3424/4885TDP1 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.